文献速递药物相互作用治疗药物监测与药物基因组学

双氯西林对窄治疗窗药物苯妥英和华法林药代动力学的影响

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin.
PubMed 文献 · Clin Pharmacol Ther · 2026-08-03

结果显示双氯西林显著增加华法林对映体及苯妥英的口服清除率,并降低INR曲线下面积。

要点

  • 双氯西林使(S)-华法林和(R)-华法林口服清除率分别增加53.2%和63.2%。
  • 双氯西林使苯妥英口服清除率和p-HPPH生成清除率分别增加42.4%和40.5%。
  • 启用双氯西林时应增加窄治疗窗CYP2C9底物剂量并密切监测。

核心结论

  • 双氯西林显著诱导华法林和苯妥英的代谢,降低华法林的抗凝效应。
  • CYP2C9*1/*1基因型携带者的CYP2C9诱导程度更大,VKORC1 AA单倍型携带者INR降低更明显。

研究设计与样本

  • 受试者接受单剂华法林20mg和一周后单剂苯妥英300mg,分别在双氯西林500mg每日四次连用21天前后进行药代动力学比较。
  • 采用验证的HPLC法测定华法林对映体和苯妥英的血浆浓度及尿中p-HPPH浓度,并通过系列INR监测华法林药效学长达120小时。

主要发现

  • 双氯西林使(S)-华法林和(R)-华法林的口服清除率分别增加53.2%和63.2%(P < 0.001)。
  • INR-时间曲线下面积降低15.5%(P < 0.001)。
  • 苯妥英口服清除率和p-HPPH生成清除率分别增加42.4%和40.5%(P < 0.001)。
  • CYP2C9诱导在CYP2C9*1/*1基因型携带者中显著更大,INR降低在VKORC1 AA单倍型携带者中更明显。

关键数值与推荐

  • 双氯西林500mg每日四次连用21天。
  • 华法林单剂20mg,苯妥英单剂300mg。
  • (S)-华法林口服清除率增加53.2%,(R)-华法林增加63.2%(P < 0.001)。
  • INR-时间曲线下面积降低15.5%(P < 0.001)。
  • 苯妥英口服清除率增加42.4%,p-HPPH生成清除率增加40.5%(P < 0.001)。

临床怎么用

  • 当开始使用双氯西林时,应增加经CYP2C9代谢且治疗窗窄的底物药物剂量。
  • 密切监测华法林和苯妥英的血药浓度和/或药效学反应(如INR)。
  • 对于CYP2C9*1/*1基因型或VKORC1 AA单倍型携带者,可能需更关注相互作用程度。

局限性

  • 研究为开放标签设计,非盲法。
  • 样本为健康受试者,非患者人群。
  • 仅评估单剂华法林和苯妥英,未评估长期合用时的稳态相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dicloxacillin is a penicillinase-resistant beta-lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin-treated patients and increases the risk of thromboembolic events. This open-label, sequential drug-drug interaction study quantitatively evaluated the effect of dicloxacillin on the pharmacokinetics of warfarin and phenytoin, two prototype CYP2C9 substrates with narrow therapeutic indices, and possible impact of CYP2C9 polymorphisms on the extent of this interaction. Twenty-eight healthy non-smoker subjects, 15 carriers of CYP2C9*1/*1, and 13 carriers of a single CYP2C9*2 or CYP2C9*3 allele, received single doses of warfarin (20 mg) and 1 week later, phenytoin (300 mg) before and during a 21-day course of dicloxacillin 500 mg four times daily. Plasma concentration of warfarin enantiomers and phenytoin and urine concentration of p-HPPH were measured using validated HPLC methods. Warfarin pharmacodynamics was monitored via serial INR measurements for up to 120 hours. Dicloxacillin increased oral clearance of (S)-warfarin and (R)-warfarin by 53.2% and 63.2%, respectively (P < 0.001). The area under the INR-time curve decreased by 15.5% (P < 0.001). Phenytoin oral clearance and p-HPPH formation clearance increased by 42.4% and 40.5%, respectively (P < 0.001). CYP2C9 induction was significantly greater in carriers of CYP2C9*1/*1 genotype and INR reduction was more pronounced among VKORC1 AA haplotype carriers. Dicloxacillin substantially induces the metabolism of warfarin and phenytoin. Whenever dicloxacillin is initiated, the dose of CYP2C9 substrates characterized by a narrow therapeutic window should be increased and drug levels and/or pharmacodynamic response should be closely monitored.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Shaul C, Mujahed W, Idries I, et al. The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin. Clin Pharmacol Ther. 2026. PMID: 42544696. doi:10.1002/cpt.70413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。